The document provides guidelines from the American Association of Clinical Endocrinologists and American College of Endocrinology for developing a comprehensive diabetes care plan. It outlines 24 questions on various aspects of diabetes management and provides 67 evidence-based recommendations. It also describes the objectives and structure of the guidelines, including evidence ratings and grades.
Memorias Conferencia Científica Anual sobre Síndrome Metabólico 2017 - Programa Científico
Futuro en el tratamiento de la DM2
Dr. Guillermo E. Umpierrez
Professor of Medicine in the Division of Endocrinology at Emory University School of Medicine, Section Head, Diabetes and Endocrinology. USA. Editor en Jefe del BJM Open Diabetes Research and Care
Memorias Conferencia Científica Anual sobre Síndrome Metabólico 2017 - Programa Científico
Manejo de la diabetes en el anciano
Dr. Guillermo E. Umpierrez
Professor of Medicine in the Division of Endocrinology at Emory University School of Medicine, Section Head, Diabetes and Endocrinology. USA. Editor en Jefe del BJM Open Diabetes Research and Care.
Summary of american diabetes association 2014 guidelinesDr. Afzal Haq Asif
The document summarizes guidelines from the American Diabetes Association (ADA) 2014 standards of medical care for diabetes. It provides recommendations on diagnosing and testing for diabetes, treatment targets for blood glucose, blood pressure, and lipids. It also discusses pharmacologic therapy, monitoring, cardiovascular disease screening and treatment, and management of other diabetes-related health issues. The full source document from the ADA contains more detailed recommendations and evidence ratings.
The document discusses guidelines for caring for elderly patients with diabetes in primary care. It recommends regularly assessing patients' functional status and adjusting glycemic targets higher for elderly patients. Treatment should be individualized, avoid complex regimens, and focus on preventing hypoglycemia. Close monitoring is needed for diabetes complications while considering other common geriatric issues.
1. The Diabetes Prevention Program (DPP) found that an intensive lifestyle intervention aimed at 7% weight loss was more effective than metformin or placebo at preventing diabetes in patients with prediabetes over 3 years, with a 58% reduction in relative risk.
2. For Mrs. K, an intensive lifestyle intervention targeting at least 7% weight loss would be the recommended first-line evidence-based approach based on the DPP findings.
3. After 1 year of lifestyle changes, Mrs. K had achieved 6% weight loss and normal fasting glucose and A1C levels, indicating response to treatment. However, 12 months later with 10 pounds regained, her glucose levels have
This document discusses the clinical management of elderly patients with diabetes. It addresses several topics:
1. Elderly patients have a different pathophysiology compared to younger adults due to changes in muscle mass, adipose tissue, and vascular function.
2. Elderly patients face higher risks of vascular complications, functional decline, falls and fractures, cognitive impairment, and mortality compared to those without diabetes.
3. A comprehensive assessment of elderly patients with diabetes should consider medical, functional, cognitive, social, and other factors to determine individualized treatment goals that preserve quality of life.
4. The management of elderly diabetes patients should focus on preventing frailty and disability rather than only treating the disease itself. Integrated
The document discusses challenges, goals and therapeutics in treating diabetes in the elderly. It notes that the incidence of diabetes increases with age until around 65 years old. Older adults with diabetes may have newly diagnosed or long-standing disease. Guidelines recommend individualizing treatment based on factors like comorbidities, risk of hypoglycemia, and life expectancy. Consensus recommendations include targeting an A1C of 7-7.5% for healthy older adults and 7.6-8.5% for frail patients, considering metformin or sulfonylureas as first-line therapy, and assessing cardiovascular and fall risks.
Memorias Conferencia Científica Anual sobre Síndrome Metabólico 2017 - Programa Científico
Futuro en el tratamiento de la DM2
Dr. Guillermo E. Umpierrez
Professor of Medicine in the Division of Endocrinology at Emory University School of Medicine, Section Head, Diabetes and Endocrinology. USA. Editor en Jefe del BJM Open Diabetes Research and Care
Memorias Conferencia Científica Anual sobre Síndrome Metabólico 2017 - Programa Científico
Manejo de la diabetes en el anciano
Dr. Guillermo E. Umpierrez
Professor of Medicine in the Division of Endocrinology at Emory University School of Medicine, Section Head, Diabetes and Endocrinology. USA. Editor en Jefe del BJM Open Diabetes Research and Care.
Summary of american diabetes association 2014 guidelinesDr. Afzal Haq Asif
The document summarizes guidelines from the American Diabetes Association (ADA) 2014 standards of medical care for diabetes. It provides recommendations on diagnosing and testing for diabetes, treatment targets for blood glucose, blood pressure, and lipids. It also discusses pharmacologic therapy, monitoring, cardiovascular disease screening and treatment, and management of other diabetes-related health issues. The full source document from the ADA contains more detailed recommendations and evidence ratings.
The document discusses guidelines for caring for elderly patients with diabetes in primary care. It recommends regularly assessing patients' functional status and adjusting glycemic targets higher for elderly patients. Treatment should be individualized, avoid complex regimens, and focus on preventing hypoglycemia. Close monitoring is needed for diabetes complications while considering other common geriatric issues.
1. The Diabetes Prevention Program (DPP) found that an intensive lifestyle intervention aimed at 7% weight loss was more effective than metformin or placebo at preventing diabetes in patients with prediabetes over 3 years, with a 58% reduction in relative risk.
2. For Mrs. K, an intensive lifestyle intervention targeting at least 7% weight loss would be the recommended first-line evidence-based approach based on the DPP findings.
3. After 1 year of lifestyle changes, Mrs. K had achieved 6% weight loss and normal fasting glucose and A1C levels, indicating response to treatment. However, 12 months later with 10 pounds regained, her glucose levels have
This document discusses the clinical management of elderly patients with diabetes. It addresses several topics:
1. Elderly patients have a different pathophysiology compared to younger adults due to changes in muscle mass, adipose tissue, and vascular function.
2. Elderly patients face higher risks of vascular complications, functional decline, falls and fractures, cognitive impairment, and mortality compared to those without diabetes.
3. A comprehensive assessment of elderly patients with diabetes should consider medical, functional, cognitive, social, and other factors to determine individualized treatment goals that preserve quality of life.
4. The management of elderly diabetes patients should focus on preventing frailty and disability rather than only treating the disease itself. Integrated
The document discusses challenges, goals and therapeutics in treating diabetes in the elderly. It notes that the incidence of diabetes increases with age until around 65 years old. Older adults with diabetes may have newly diagnosed or long-standing disease. Guidelines recommend individualizing treatment based on factors like comorbidities, risk of hypoglycemia, and life expectancy. Consensus recommendations include targeting an A1C of 7-7.5% for healthy older adults and 7.6-8.5% for frail patients, considering metformin or sulfonylureas as first-line therapy, and assessing cardiovascular and fall risks.
The DAWN2 study aims to assess barriers and facilitators to diabetes self-management through a multinational survey of people with diabetes, their family members, and healthcare professionals across 17 countries. The study goals are to understand unmet needs, identify opportunities for improvement, and inform advocacy efforts to advance person-centered diabetes care and prevention globally. Initial findings provide insights into concerns, treatment attitudes, and access to support services across stakeholder groups.
This document discusses post-transplant diabetes mellitus (PTDM), including its definition, risk factors, pathophysiology, diagnosis, differences from other types of diabetes, effects on transplant outcomes, and management challenges. PTDM prevalence varies in studies from 10-15% to as high as 50-60% depending on factors like definition and population. Risk factors include use of immunosuppressive drugs like tacrolimus and steroids, in addition to traditional diabetes risk factors. Diagnosis can be difficult in the first year after transplant due to reliability issues with HbA1c and glucose tests. PTDM worsens outcomes for liver and kidney transplants but has less impact on heart transplants. Management requires careful consideration of drug
This document discusses the management of diabetes in elderly patients. It notes that diabetes prevalence is increasing globally and is especially prevalent in aging populations due to increased complexity, comorbidities, and risk of functional decline. Proper management of elderly diabetes requires individualized, holistic care plans focused on safety, risk minimization, and maintaining quality of life. Key aspects of care include education, nutrition, exercise, medication management, screening and prevention of complications, and management of comorbidities like cardiovascular disease.
Modern modalities for management of diabetes dr mahir jallo gulf medical univ...Mahir Khalil Ibrahim Jallo
This document discusses modern modalities for managing diabetes. It begins by defining the main types of diabetes - type 1, type 2, and gestational diabetes. It then discusses diabetes complications and treatments, including various classes of oral medications and insulins to manage blood glucose levels. Newer classes of medications that work by different mechanisms, such as DPP-4 inhibitors and SGLT2 inhibitors, are also covered. The document emphasizes the importance of a multifactorial treatment approach to diabetes management.
This document summarizes diabetic kidney disease (DKD), the leading cause of end-stage renal disease in the United States. DKD risk factors include age, sex, race, family history, hypertension, and poor glycemic control. Intensive glucose and blood pressure control can delay DKD progression. While current therapies can slow DKD, innovation is still needed to improve outcomes given residual risks. Novel drug classes targeting DKD mechanisms may provide future treatment options.
The document discusses guidelines for classifying, diagnosing, and managing diabetes and prediabetes. It covers:
1. Classification of diabetes into types 1, 2, gestational and other specific types.
2. Criteria for diagnosing diabetes based on HbA1c, fasting plasma glucose and oral glucose tolerance tests.
3. Recommendations for screening and testing for prediabetes and diabetes in asymptomatic individuals.
The document summarizes recommendations from the 2016 American Diabetes Association guidelines. It provides criteria for diagnosing diabetes and prediabetes based on HbA1c, fasting plasma glucose, and oral glucose tolerance test results. It recommends screening for type 2 diabetes in asymptomatic adults aged 45 or older who are overweight or have additional risk factors, as well as screening children who are overweight and have certain risk factors. Guidelines for screening gestational diabetes and type 1 diabetes are also presented.
This document provides an overview of diabetes management guidelines from the American Diabetes Association. It defines diabetes, classifies the different types, and outlines diagnostic criteria. It discusses the major components of treatment including medical nutrition therapy, physical activity, smoking cessation, comprehensive medical evaluation, glycemic targets, glucose monitoring, and pharmacological therapies. Glycemic goals and treatment approaches are presented for both type 1 and type 2 diabetes in adults and children.
Post transplant diabetes mellitus (PTDM) is a type of diabetes that can develop after an organ transplant. The prevalence of PTDM ranges from 10-60% depending on the study and definition used. Many factors contribute to the risk of developing PTDM, including certain immunosuppressive medications, family history of diabetes, and acute rejection episodes. PTDM is associated with worse outcomes for transplant recipients, including higher rates of infection, rejection, and decreased graft and patient survival. Effective management of PTDM requires consideration of drug interactions between glucose lowering medications and immunosuppressants, as well as monitoring for complications related to both conditions.
Estudios que evaluaron el tratamiento actual de la hepatitis C, los cuales fueron presentados en el consenso de viena en abril de 2015.
Forman parte de EASL guidelines HCV 2015.
1. The study aimed to compare the blood glucose lowering effects of the traditional Indian plant Vijayasar (Pterocarpus marsupium) and the pharmaceutical agent tolbutamide in managing diabetes.
2. A total of 365 newly diagnosed type 2 diabetes patients were randomized to receive either Vijayasar or tolbutamide for 36 weeks.
3. The results showed that Vijayasar was as effective as tolbutamide in lowering blood glucose with no significant differences in effects on lipids or safety profiles.
This document provides guidelines for the evaluation and management of chronic kidney disease (CKD) developed by the Kidney Disease: Improving Global Outcomes (KDIGO) organization. It defines CKD and staging systems based on glomerular filtration rate and albuminuria levels. The guidelines provide recommendations on screening and diagnosis of CKD, predicting progression, managing risk factors and complications, and referral to specialists. CKD is a major global public health problem, and these evidence-based guidelines aim to aid healthcare providers in delivering optimal care to patients with CKD.
American association of clinical endocrinologists and ace comprehensive care ...Sachin Shende
This document presents guidelines from the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) for developing a comprehensive care plan for patients with diabetes mellitus (DM). It was created by a task force consisting of over 30 endocrinologists and updates 2011 guidelines. The guidelines provide 67 evidence-based recommendations across 24 questions to guide clinicians in providing integrated care focused on microvascular/macrovascular risk factors beyond just glycemic control. The recommendations emphasize individualized treatment goals for weight, glucose, lipids, blood pressure, and safety over efficacy. The guidelines are intended to serve as an education and decision-making resource for clinicians caring for patients with DM.
Slides on Diabetes in the South Focus on Prevention.2018hivlifeinfo
Learn how to overcome common barriers to diabetes prevention with this downloadable slideset.
Richard E. Pratley, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.16 MB
Released: October 23, 2018
The document outlines standards of medical care for diabetes in 2011 as published by the American Diabetes Association (ADA). It includes recommendations for classifying and diagnosing diabetes, testing asymptomatic patients, detecting gestational diabetes, preventing type 2 diabetes, initial diabetes care evaluations, and monitoring and treating diabetes and its complications. The recommendations are evidence-based, graded according to level of evidence from A to E. Components of an initial comprehensive diabetes evaluation are also outlined.
Ueda 2016 hypertension & diabetes - gamila nasrueda2015
The document discusses guidelines for managing hypertension in patients with diabetes. It states that hypertension is more prevalent in diabetic patients compared to non-diabetic patients, with the diagnostic cutoff being 140/90 mmHg rather than 150/95 mmHg. The main recommendations are that treatment should target a blood pressure of below 130/80 mmHg using an ACE inhibitor, ARB, CCB, or thiazide diuretic initially. Multiple drugs are often needed to reach target blood pressure levels, and careful monitoring is recommended for those with kidney disease on ACE inhibitors or ARBs.
This document provides standards of care for diabetes management as established by the American Diabetes Association (ADA). It discusses the classification and diagnosis of diabetes, including the criteria for diagnosing diabetes based on A1C, fasting plasma glucose, and oral glucose tolerance tests. It also defines categories of increased risk for diabetes, also known as prediabetes. The standards are intended to provide guidance to clinicians and others on the components of diabetes care and treatment goals.
This document discusses driving impairment related to various neurological disorders. It summarizes evidence and guidelines around driving in epilepsy, dementia, Parkinson's disease, and after stroke. For epilepsy, most studies focus on minimum seizure-free periods required before driving again, ranging from 3 months to 1 year depending on the jurisdiction. For dementia, clinical features like CDR scores and history of accidents or citations predict unsafe driving. Guidelines help physicians evaluate driving risk. Overall, the document ties together considerations and evidence around determining fitness to drive for different neurological conditions.
This document provides standards of care for diabetes management and treatment. It summarizes guidelines for classifying and diagnosing diabetes, testing for pre-diabetes and diabetes in asymptomatic individuals, and detecting and diagnosing gestational diabetes. The standards are intended to improve diabetes outcomes by providing evidence-based recommendations to help clinicians provide quality care and treatment.
The document discusses strategies for identifying and managing patients at high risk for diabetes. It finds that intensive lifestyle interventions or metformin treatment can significantly reduce the risk of developing diabetes in patients identified as having prediabetes, defined as impaired glucose tolerance and/or impaired fasting glucose based on oral glucose tolerance tests. However, A1C screening has become more common in primary care settings, but its ability to identify patients most likely to benefit from prevention programs is unclear since such programs have focused on patients identified through tolerance tests. The document advocates for further testing, such as with oral glucose tolerance tests or alternative tests like Quantose, of patients found to have A1C levels in the prediabetes range to better identify which patients have impaired glucose tolerance
This document provides guidelines from the American Diabetes Association for the standards of medical care in diabetes. It discusses the classification and diagnosis of diabetes, including the criteria for diagnosing diabetes based on A1C, fasting plasma glucose, and oral glucose tolerance tests. It also defines categories of increased risk for diabetes, also known as prediabetes. The guidelines are intended to provide clinicians, patients, and others with the components of diabetes care and treatment goals.
The DAWN2 study aims to assess barriers and facilitators to diabetes self-management through a multinational survey of people with diabetes, their family members, and healthcare professionals across 17 countries. The study goals are to understand unmet needs, identify opportunities for improvement, and inform advocacy efforts to advance person-centered diabetes care and prevention globally. Initial findings provide insights into concerns, treatment attitudes, and access to support services across stakeholder groups.
This document discusses post-transplant diabetes mellitus (PTDM), including its definition, risk factors, pathophysiology, diagnosis, differences from other types of diabetes, effects on transplant outcomes, and management challenges. PTDM prevalence varies in studies from 10-15% to as high as 50-60% depending on factors like definition and population. Risk factors include use of immunosuppressive drugs like tacrolimus and steroids, in addition to traditional diabetes risk factors. Diagnosis can be difficult in the first year after transplant due to reliability issues with HbA1c and glucose tests. PTDM worsens outcomes for liver and kidney transplants but has less impact on heart transplants. Management requires careful consideration of drug
This document discusses the management of diabetes in elderly patients. It notes that diabetes prevalence is increasing globally and is especially prevalent in aging populations due to increased complexity, comorbidities, and risk of functional decline. Proper management of elderly diabetes requires individualized, holistic care plans focused on safety, risk minimization, and maintaining quality of life. Key aspects of care include education, nutrition, exercise, medication management, screening and prevention of complications, and management of comorbidities like cardiovascular disease.
Modern modalities for management of diabetes dr mahir jallo gulf medical univ...Mahir Khalil Ibrahim Jallo
This document discusses modern modalities for managing diabetes. It begins by defining the main types of diabetes - type 1, type 2, and gestational diabetes. It then discusses diabetes complications and treatments, including various classes of oral medications and insulins to manage blood glucose levels. Newer classes of medications that work by different mechanisms, such as DPP-4 inhibitors and SGLT2 inhibitors, are also covered. The document emphasizes the importance of a multifactorial treatment approach to diabetes management.
This document summarizes diabetic kidney disease (DKD), the leading cause of end-stage renal disease in the United States. DKD risk factors include age, sex, race, family history, hypertension, and poor glycemic control. Intensive glucose and blood pressure control can delay DKD progression. While current therapies can slow DKD, innovation is still needed to improve outcomes given residual risks. Novel drug classes targeting DKD mechanisms may provide future treatment options.
The document discusses guidelines for classifying, diagnosing, and managing diabetes and prediabetes. It covers:
1. Classification of diabetes into types 1, 2, gestational and other specific types.
2. Criteria for diagnosing diabetes based on HbA1c, fasting plasma glucose and oral glucose tolerance tests.
3. Recommendations for screening and testing for prediabetes and diabetes in asymptomatic individuals.
The document summarizes recommendations from the 2016 American Diabetes Association guidelines. It provides criteria for diagnosing diabetes and prediabetes based on HbA1c, fasting plasma glucose, and oral glucose tolerance test results. It recommends screening for type 2 diabetes in asymptomatic adults aged 45 or older who are overweight or have additional risk factors, as well as screening children who are overweight and have certain risk factors. Guidelines for screening gestational diabetes and type 1 diabetes are also presented.
This document provides an overview of diabetes management guidelines from the American Diabetes Association. It defines diabetes, classifies the different types, and outlines diagnostic criteria. It discusses the major components of treatment including medical nutrition therapy, physical activity, smoking cessation, comprehensive medical evaluation, glycemic targets, glucose monitoring, and pharmacological therapies. Glycemic goals and treatment approaches are presented for both type 1 and type 2 diabetes in adults and children.
Post transplant diabetes mellitus (PTDM) is a type of diabetes that can develop after an organ transplant. The prevalence of PTDM ranges from 10-60% depending on the study and definition used. Many factors contribute to the risk of developing PTDM, including certain immunosuppressive medications, family history of diabetes, and acute rejection episodes. PTDM is associated with worse outcomes for transplant recipients, including higher rates of infection, rejection, and decreased graft and patient survival. Effective management of PTDM requires consideration of drug interactions between glucose lowering medications and immunosuppressants, as well as monitoring for complications related to both conditions.
Estudios que evaluaron el tratamiento actual de la hepatitis C, los cuales fueron presentados en el consenso de viena en abril de 2015.
Forman parte de EASL guidelines HCV 2015.
1. The study aimed to compare the blood glucose lowering effects of the traditional Indian plant Vijayasar (Pterocarpus marsupium) and the pharmaceutical agent tolbutamide in managing diabetes.
2. A total of 365 newly diagnosed type 2 diabetes patients were randomized to receive either Vijayasar or tolbutamide for 36 weeks.
3. The results showed that Vijayasar was as effective as tolbutamide in lowering blood glucose with no significant differences in effects on lipids or safety profiles.
This document provides guidelines for the evaluation and management of chronic kidney disease (CKD) developed by the Kidney Disease: Improving Global Outcomes (KDIGO) organization. It defines CKD and staging systems based on glomerular filtration rate and albuminuria levels. The guidelines provide recommendations on screening and diagnosis of CKD, predicting progression, managing risk factors and complications, and referral to specialists. CKD is a major global public health problem, and these evidence-based guidelines aim to aid healthcare providers in delivering optimal care to patients with CKD.
American association of clinical endocrinologists and ace comprehensive care ...Sachin Shende
This document presents guidelines from the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) for developing a comprehensive care plan for patients with diabetes mellitus (DM). It was created by a task force consisting of over 30 endocrinologists and updates 2011 guidelines. The guidelines provide 67 evidence-based recommendations across 24 questions to guide clinicians in providing integrated care focused on microvascular/macrovascular risk factors beyond just glycemic control. The recommendations emphasize individualized treatment goals for weight, glucose, lipids, blood pressure, and safety over efficacy. The guidelines are intended to serve as an education and decision-making resource for clinicians caring for patients with DM.
Slides on Diabetes in the South Focus on Prevention.2018hivlifeinfo
Learn how to overcome common barriers to diabetes prevention with this downloadable slideset.
Richard E. Pratley, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.16 MB
Released: October 23, 2018
The document outlines standards of medical care for diabetes in 2011 as published by the American Diabetes Association (ADA). It includes recommendations for classifying and diagnosing diabetes, testing asymptomatic patients, detecting gestational diabetes, preventing type 2 diabetes, initial diabetes care evaluations, and monitoring and treating diabetes and its complications. The recommendations are evidence-based, graded according to level of evidence from A to E. Components of an initial comprehensive diabetes evaluation are also outlined.
Ueda 2016 hypertension & diabetes - gamila nasrueda2015
The document discusses guidelines for managing hypertension in patients with diabetes. It states that hypertension is more prevalent in diabetic patients compared to non-diabetic patients, with the diagnostic cutoff being 140/90 mmHg rather than 150/95 mmHg. The main recommendations are that treatment should target a blood pressure of below 130/80 mmHg using an ACE inhibitor, ARB, CCB, or thiazide diuretic initially. Multiple drugs are often needed to reach target blood pressure levels, and careful monitoring is recommended for those with kidney disease on ACE inhibitors or ARBs.
This document provides standards of care for diabetes management as established by the American Diabetes Association (ADA). It discusses the classification and diagnosis of diabetes, including the criteria for diagnosing diabetes based on A1C, fasting plasma glucose, and oral glucose tolerance tests. It also defines categories of increased risk for diabetes, also known as prediabetes. The standards are intended to provide guidance to clinicians and others on the components of diabetes care and treatment goals.
This document discusses driving impairment related to various neurological disorders. It summarizes evidence and guidelines around driving in epilepsy, dementia, Parkinson's disease, and after stroke. For epilepsy, most studies focus on minimum seizure-free periods required before driving again, ranging from 3 months to 1 year depending on the jurisdiction. For dementia, clinical features like CDR scores and history of accidents or citations predict unsafe driving. Guidelines help physicians evaluate driving risk. Overall, the document ties together considerations and evidence around determining fitness to drive for different neurological conditions.
This document provides standards of care for diabetes management and treatment. It summarizes guidelines for classifying and diagnosing diabetes, testing for pre-diabetes and diabetes in asymptomatic individuals, and detecting and diagnosing gestational diabetes. The standards are intended to improve diabetes outcomes by providing evidence-based recommendations to help clinicians provide quality care and treatment.
The document discusses strategies for identifying and managing patients at high risk for diabetes. It finds that intensive lifestyle interventions or metformin treatment can significantly reduce the risk of developing diabetes in patients identified as having prediabetes, defined as impaired glucose tolerance and/or impaired fasting glucose based on oral glucose tolerance tests. However, A1C screening has become more common in primary care settings, but its ability to identify patients most likely to benefit from prevention programs is unclear since such programs have focused on patients identified through tolerance tests. The document advocates for further testing, such as with oral glucose tolerance tests or alternative tests like Quantose, of patients found to have A1C levels in the prediabetes range to better identify which patients have impaired glucose tolerance
This document provides guidelines from the American Diabetes Association for the standards of medical care in diabetes. It discusses the classification and diagnosis of diabetes, including the criteria for diagnosing diabetes based on A1C, fasting plasma glucose, and oral glucose tolerance tests. It also defines categories of increased risk for diabetes, also known as prediabetes. The guidelines are intended to provide clinicians, patients, and others with the components of diabetes care and treatment goals.
This document provides an overview of diabetes including:
- Incidence rates of diabetes are increasing in the US and Maine. Rates vary between racial/ethnic groups.
- Diabetes is classified and diagnosed based on measurements like fasting plasma glucose, A1C, and oral glucose tolerance tests.
- Risk factors for diabetes include obesity, family history, race/ethnicity, and other medical conditions. Screening is recommended for those with risk factors.
- Complications of diabetes include microvascular issues like retinopathy and neuropathy, and macrovascular issues like heart disease and stroke. Preventative care and treatment of risk factors can reduce complications.
This document provides guidelines for diagnosing and classifying diabetes. It recommends using A1C, fasting plasma glucose, or oral glucose tolerance tests to diagnose diabetes, with A1C ≥6.5%, fasting plasma glucose ≥126 mg/dL, or 2-hour plasma glucose ≥200 mg/dL meeting the diagnostic thresholds. It also defines prediabetes categories as A1C 5.7-6.4%, fasting plasma glucose 100-125 mg/dL, or 2-hour plasma glucose 140-199 mg/dL to identify individuals at increased risk. The guidelines are intended to provide clinicians with the components of diabetes care and treatment goals to evaluate quality of care.
This document provides standards of care for diabetes management as established by the American Diabetes Association (ADA). It discusses the classification and diagnosis of diabetes, including the criteria for diagnosing diabetes based on A1C, fasting plasma glucose, and oral glucose tolerance tests. It also defines categories of increased risk for diabetes, also known as prediabetes. The standards are intended to provide guidance to clinicians and others on the components of diabetes care and treatment goals.
This document discusses treatment of type 1 diabetes (T1D). The goals of T1D management are near-normal blood glucose and A1C levels while preventing complications. Routine care recommendations include regular checkups, testing, and screenings. Intensive insulin therapy aimed at an A1C below 7% has been shown to significantly reduce risks of complications, though it carries a higher risk of hypoglycemia. New insulin analogues, insulin pumps, home glucose monitoring, and continuous glucose monitoring have advanced T1D treatment. The basal-bolus insulin regimen uses a basal insulin to maintain blood glucose levels between meals combined with bolus insulins before meals.
This document provides guidelines for screening, diagnosing, and managing diabetes and its complications. It recommends:
- Screening everyone over 40 every 3 years for diabetes using HbA1c, fasting plasma glucose, or oral glucose tolerance tests. Screen more often for those at high risk.
- Targeting an HbA1c of less than 7% for most patients. Consider a target of 7.1-8.5% for those with comorbidities or risk of hypoglycemia.
- Treating diabetes with lifestyle changes like nutrition therapy and exercise. If needed, add metformin and/or additional medications based on individual factors.
- Prescribing statins, ACE inhibitors or ARBs, and
Managing diabetes in primary care in the caribbeanAndre Sookdar
The document provides a critical appraisal of diabetes management guidelines produced by the Caribbean Health Research Council (CHRC). The guidelines aim to establish a unified, evidence-based approach to diabetes care in the Caribbean. They include definitions of diabetes, screening and diagnostic criteria, targets for metabolic control, guidelines for treatment and management, and goals for patient education. While the appraisal finds that the guidelines focus on primary prevention and cost-effectiveness, it notes that details around conflicts of interest and the rigor of the literature review were not provided. Overall, the guidelines are deemed simple, cost-effective and suitable for implementation in primary care practices.
This document discusses a study on the incidence of macrovascular complications in newly diagnosed diabetic patients. The study aims to examine the occurrence of complications like cardiovascular disease, cerebrovascular disease, and peripheral vascular disease within 6 months of diabetes diagnosis. The methodology describes collecting data on risk factors, examinations, and investigations from diabetic patients. Preliminary results found cardiovascular disease in 40% of new diabetics, cerebrovascular complications in 10%, and peripheral vascular disease in 8%. Incidence was higher in patients with risk factors like hypertension, dyslipidemia, obesity, smoking, and family history of diabetes.
Vitamin D status in children with type 1 diabetes mellitusAzad Haleem
The document discusses vitamin D and its role in type 1 diabetes (T1D). It finds that children with T1D have significantly lower levels of vitamin D compared to healthy children. Vitamin D levels were also lower in patients with longer diabetes duration and poorer glycemic control. However, no significant association was found between vitamin D levels and BMI. The document recommends vitamin D supplementation may help improve outcomes for T1D patients and that further research is needed to better understand the relationship between vitamin D and T1D.
Non-alcoholic fatty liver disease (NAFLD) is the buildup of excess fat in the liver not caused by alcohol. It is commonly caused by diet and lack of exercise and affects up to 30% of adults in the United States. Those at high risk often have weight issues, type 2 diabetes, high blood pressure, high cholesterol or high triglycerides. While NAFLD may cause no symptoms, it can potentially lead to liver inflammation, scarring, cancer or failure if fat accounts for over 5% of the liver's weight. Maintaining a healthy weight and lifestyle through diet and exercise can help prevent NAFLD.
Salon 2 13 kasim 14.00 15.00 serpi̇l akkuş topçu-ingtyfngnc
This document discusses acute coronary syndromes, risk factors, and prevention. It provides an overview of coronary artery disease and its clinical signs. It then examines major cardiovascular disease risk factors such as smoking, overweight/obesity, physical inactivity, hypertension, alcohol, and diabetes. Prevention strategies are outlined for each risk factor, including the nursing role in primary and secondary prevention. The document also discusses social determinants of cardiovascular health and the importance of prevention beginning in fetal life, childhood, and youth.
Based on the evidence presented in the document, the appropriate recommendation for Mrs. K would be a lifestyle intervention with a goal of 7% weight loss (Option B). The DPP trial demonstrated that lifestyle intervention, aimed at 7% weight loss through diet and exercise, reduced the risk of developing diabetes by 58% over 3 years compared to placebo. This lifestyle intervention was more effective than metformin alone in preventing diabetes.
The document summarizes recommendations from the 2016 American Diabetes Association (ADA) diabetes guidelines. Key points include: criteria for diagnosing diabetes; recommendations for screening for type 1, type 2, and gestational diabetes; glycemic targets and management of hypoglycemia; strategies for preventing type 2 diabetes; and pharmacologic therapy options for type 2 diabetes management. The full ADA guidelines provide additional details and evidence ratings for each recommendation.
This document presents standards of care for diabetes published by the American Diabetes Association. It discusses that diabetes requires ongoing medical care and patient self-management to prevent complications. The standards are intended to provide guidance on treatment goals and quality of care evaluation. The recommendations are based on evidence from screening, diagnostic and therapeutic interventions shown to positively impact health outcomes. The standards are revised annually based on new evidence and committee review.
This document discusses cardiometabolic risk, which refers to the risks associated with metabolic changes that can lead to cardiovascular disease. It defines cardiometabolic risk and identifies both non-modifiable and modifiable risk factors such as obesity, dyslipidemia, hypertension, smoking, and physical inactivity. The document emphasizes the importance of early identification and management of risk factors through comprehensive patient assessment and targeted intervention to prevent diseases like cardiovascular disease and diabetes.
C15 ada standards of medical care in diabetes 2012Diabetes for all
This document provides standards of care for diabetes management and treatment. It discusses that diabetes requires ongoing medical care and patient self-management to prevent complications. The standards are intended to guide clinicians and other stakeholders in evaluating quality of care and setting treatment goals, while allowing for flexibility based on individual patient factors. Diagnosis of diabetes can be made based on hemoglobin A1c, fasting plasma glucose, or oral glucose tolerance test results.
This document presents standards of care for diabetes published by the American Diabetes Association. It discusses that diabetes requires ongoing medical care and patient self-management to prevent complications. The standards provide clinicians and others components of diabetes care, treatment goals, and ways to evaluate quality of care, while allowing for customization based on individual patient factors. The recommendations are based on evidence from screening, diagnostic and therapeutic interventions shown to positively impact patient health outcomes and be cost-effective.
Treating Cholesterol in Asian Patients: Balancing the Risk and Benefitsahvc0858
This document summarizes a presentation on treating cholesterol in Asians given by Dr. Jeremy Chow. It discusses the prevalence of hyperlipidemia in Singapore, challenges with statin usage in Asians including common myths, and new cholesterol targets for high-risk patients. It provides examples of managing different patient cases, including lifestyle modifications, medications such as statins and PCSK9 inhibitors, and balancing risks and benefits of treatment.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!